HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

AbstractPURPOSE:
Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial.
PATIENTS AND METHODS:
Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point.
RESULTS:
All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression.
CONCLUSION:
Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.
AuthorsShaoliang Chen, Like Yu, Changying Jiang, Yan Zhao, Da Sun, Shenyu Li, Guoqing Liao, Yangchun Chen, Qing Fu, Qun Tao, Dan Ye, Peisheng Hu, Leslie A Khawli, Clive R Taylor, Alan L Epstein, Dian Wen Ju
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 23 Issue 7 Pg. 1538-47 (Mar 01 2005) ISSN: 0732-183X [Print] United States
PMID15735129 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Neoplasm
  • Immunotoxins
  • Iodine Radioisotopes
Topics
  • Adult
  • Aged
  • Antibodies, Neoplasm
  • Carcinoma, Non-Small-Cell Lung (diagnostic imaging, pathology, radiotherapy)
  • Female
  • Humans
  • Immunotoxins (administration & dosage)
  • Iodine Radioisotopes (administration & dosage, toxicity)
  • Lung Neoplasms (diagnostic imaging, pathology, radiotherapy)
  • Male
  • Middle Aged
  • Necrosis
  • Positron-Emission Tomography
  • Radioimmunotherapy (adverse effects, methods)
  • Tissue Distribution

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: